WASHINGTON, March 22, 2023 (GLOBE NEWSWIRE) -- Global Surgical Retractors Market is valued at USD 1,179.5 Billion in 2021 and is projected to reach a value of USD 1,626.3 Million by 2028 at a CAGR (Compound Annual Growth Rate) of 5.5% over the forecast period 2022-2028. Surgical Retractors Market Overview The surgical retractors market refers to the medical instruments used to hold an incision or wound open during surgery, allowing surgeons to view and access the area being operated on. These devices come in a variety of shapes and sizes, and they are used in a wide range of surgical procedures. The global surgical retractors market is expected to experience steady growth in the coming years. The growing prevalence of chronic diseases such as cancer and cardiovascular disease, coupled with an aging population, is expected to increase demand for surgical procedures, which will in turn drive demand for surgical retractors. Technological advancements in surgical instruments and an increasing focus on minimally invasive surgeries are also expected to fuel market growth.

WILMINGTON, DE / ACCESSWIRE / March 20, 2023 / Transparency Market Research Inc. - The global catheter introducer sheaths market was valued at USD 1.0 Bn in 2022 and is projected to reach USD 1.6 Bn by 2031 with CAGR of 5.3%. Increase in prevalence of cardiovascular diseases, advances in medical technology, surge in awareness about cardiac conditions and treatments, government support for the development of new products, and expanding geriatric population are some key factors fueling the catheter introducer sheaths market. Catheter introducer sheaths are mostly used during interventional procedures that require access to the cardiovascular system. These provide a stable pathway to introduce other medical devices into blood vessels. Request for a Sample PDF Report with Latest Industry Insights: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85444 Advances in medical technology is anticipated to create new revenue streams, and thus fuel business growth. Rise in development of new catheter sheaths, which lower the risk of contamination, help reduce procedure time, are easy to use, and provide improved patient comfort and safety, are anticipated to propel market development.

DUBLIN--(BUSINESS WIRE)--The "Global Foreign Body Removal Device Market Size, Share, & COVID-19 Impact Analysis 2023-2029" report has been added to ResearchAndMarkets.com''s offering. The global market for foreign body removal devices was valued at $10.6 million in 2022 and is predicted to rise to $12.2 million by the end of the forecast period, with a CAGR of 2.1%. The comprehensive report covers both disposable and reusable foreign body removal devices. MARKET DATA INCLUDED Unit Sales, Ave

Boston Scientific''s (NYSE: BSX ) short percent of float has risen 30.88% since its last report. The company recently reported that it has 12.69 million shares sold short , which is 0.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.8 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com

NORTHAMPTON, MA / ACCESSWIRE / March 8, 2023 / Boston Scientific Leaders play a crucial role in cultivating a culture of equity and inclusion. If culture was soil, what are the fertilizers that leaders would need to mix in for equity to blossom? I''ve been mulling over this question to recognize the theme of this year''s International Women''s Day: Embrace Equity. I''m passionate about cultivating healthy, vibrant culture, and so I was intrigued to reflect on how leaders can grow a culture where inclusion and equity are engrained in its soil. Three specific moments came to mind. Moment #1: Embracing my "otherness" During the height of the pandemic in 2020, I happened to be the only parent on the Boston Scientific executive committee with young kids at home. I found that I was that voice constantly reminding the team about the challenging and often harrowing realities of our employees who were expected to manage work, their kids'' school closures and distance learning - all at the same time.

Boston Scientific Corporation - Consensus Indicates Potential 12.3% Upside

Boston Scientific Corporation (NYSE:BSX)’s traded shares stood at 8.91 million during the last session, with the company’s beta value hitting 0.79. At the close of trading, the stock’s price was $47.01, to imply a decrease of -0.36% or -$0.17 in intraday trading. The BSX share’s 52-week high remains $48.87, putting it -3.96% down since that … Boston Scientific Corporation (NYSE: BSX): Can The Stock Still Lose Despite An 1.60% YTD Gain? Read More »

iData Research, a leading global consulting and market research firm, has released updated insights on the U.S. ERCP (endoscopic retrograde

Boston Scientific Corporation (NYSE:BSX) price on Thursday, February 23, rose 1.22% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $47.18. A look at the stock’s price movement, the close in the last trading session was $46.61, moving within a range at $46.385 and $47.27. The beta value … Boston Scientific Corporation (NYSE: BSX) Is Expected To Rise To 59.00 USD! Read More »

NORTHAMPTON, MA / ACCESSWIRE / February 22, 2023 / For the eighth consecutive year, Boston Scientific has been recognized on Fortune''s list of the World''s Most Admired Companies. Companies are sele…

NORTHAMPTON, MA / ACCESSWIRE / February 22, 2023 / For the eighth consecutive year, Boston Scientific has been recognized on Fortune''s list of the World''s Most Admired Companies. Companies are selected based on nine attributes encompassing …

Boston Scientific Corporation (NYSE:BSX) price is hovering lower on Tuesday, February 21, dropping -0.73% below its previous close. A look at today’s price movement shows that the recent level at last check reads $46.54, with intraday deals fluctuating between $46.24 and $46.79. The company’s 5Y monthly beta was ticking 0.79 while its P/E ratio in … Boston Scientific Corporation (NYSE: BSX) Drops -0.73% In Early Trade; What Lies Ahead? Read More »

In last trading session, Boston Scientific Corporation (NYSE:BSX) saw 7.96 million shares changing hands with its beta currently measuring 0.79. Company’s recent per share price level of $46.54 trading at $0.06 or 0.13% at ring of the bell on the day assigns it a market valuation of $66.42B. That closing price of BSX’s stock is … Boston Scientific Corporation (NYSE:BSX) Is -1.46% Lower Than A Week Ago, Can It Hit Well Above -$0.69? Read More »

QCOSTARICA – Boston Scientific Corporation (NYSE: BSX) – a world leader in innovative medical devices that improve the lives of patients around the world – announced the expansion of its operations by adding a third plant in Costa Rica. The new facilities are located in the province of Cartago. “We are grateful to our collaborators […]

There are two main reasons why moving averages are useful in forex trading: First Reason is moving averages help traders define trend Second Reason is recognizes changes in trend. Now … The post Intriguing stocks: Baker Hughes Company (NASDAQ:BKR 0.34%), Boston Scientific Corporation (NYSE:BSX -1.71%) appeared first on Stocks Equity .

Originally published in the Boston Globe NORTHAMPTON, MA / ACCESSWIRE / February 15, 2023 / Trevor Boylston had started transitioning from female to male a decade before he started working at Boston Scientific, and he had no plans to reveal his true self to his new coworkers. Boylston has a stocky build and a beard and is married to a woman - "seemingly straight," as he puts it. But about six months after he started at the medical device company, around the time Caitlyn Jenner transitioned, a coworker started making transgender jokes. And Boylston decided he couldn''t stay quiet any longer. Continue reading here Matisse DuPont (right) spoke to potential employers while attending the Massachusetts LGBT Chamber of Commerce''s job fair focused on the transgender community on Jan. 17.ERIN CLARK/GLOBE STAFF View additional multimedia and more ESG storytelling from Boston Scientific on 3blmedia.com. Contact Info: Spokesperson: Boston Scientific Website: https://www.3blmedia.com/profiles/boston-scientific Email: info@3blmedia.

Boston Scientific came up short on margins in Q4 2022. See why I think BSX stock may be worth a look from investors with a more flexible view on valuation.

Boston Scientific Corporation - Consensus Indicates Potential 12.6% Upside

On January 31st, 2023, a jury awarded $42 million to medical device company TissueGen in a patent infringement case against Boston Scientific for infringement of U.S. Patent No. 6,596,296, titled “Biodegradable Drug-Releasing Implant.” The ’296 patent relates to a drug releasing biodegradable fiber implant which allows for controlled delivery of therapeutic agents…. By: Knobbe Martens

Major players in the prosthetic heart valve devices and equipment market are Boston Scientific, Edward life sciences, Medtronic, Livanova, Abbott, Jenavalve technology, Lepu medical, Cryolife, Neovasc Inc, and St. Major players in the prosthetic heart valve devices and equipment market are Boston Scientific, Edward life sciences, Medtronic, Livanova, Abbott, Jenavalve technology, Lepu medical, Cryolife, Neovasc Inc, and St.

Major players in the interventional cardiology devices and equipment market are GE Healthcare, Abbott Laboratories, Boston Scientific Corporation, Medtronic Inc, Johnson & Johnson, B.Braun Melsungen AG, Biosensors International Ltd, Novacam Technologies Inc, Cook Medical LLC, and Biotronik SE & Co. Major players in the interventional cardiology devices and equipment market are GE Healthcare, Abbott Laboratories, Boston Scientific Corporation, Medtronic Inc, Johnson & Johnson, B.Braun Melsungen AG, Biosensors International Ltd, Novacam Technologies Inc, Cook Medical LLC, and Biotronik SE & Co.

Edition : 2023 The global active implantable medical devices market was valued at US$ 16,721.2 million in 2022 and is expected to witness a robust CAGR of 5.4% over the forecast period (2023-2030). The Active Implantable Medical Devices market report is designed

NORTHAMPTON, MA / ACCESSWIRE / February 9, 2023 / Originally published by WomenInc. As work-life integration stays at the forefront of our new normal, I worry that we''ve inadvertently dropped the ball on another critical conversation: career strategies. Work-life integration took on a new face over the past few years, as knowledge workers'' hidden caregiving responsibilities were forced into the spotlight (or the Zoom video screen). According to the Centers for Disease Control and Prevention, two out of every three caregivers in the United States are women -providing regular or daily support for children or adults, including those with chronic illnesses or disabilities. Continue reading here . Mary Beth Moynihan, Senior Vice President, Market Access and Chief Marketing Officer, Boston Scientific. Image Courtesy of WomenInc. View additional multimedia and more ESG storytelling from Boston Scientific on 3blmedia.com. Contact Info: Spokesperson: Boston Scientific Website: https://www.3blmedia.

Major players in the medical lasers market are El.En. S.p.A, Ellex Medical Lasers Ltd, Lumenis, Alcon Laboratories Inc, AngioDynamics Corp, American Medical Systems Inc, Biolase Inc, Bausch & Lomb Holdings, Cardiogenesis Corporation Inc, and Boston Scientific. Major players in the medical lasers market are El.En. S.p.A, Ellex Medical Lasers Ltd, Lumenis, Alcon Laboratories Inc, AngioDynamics Corp, American Medical Systems Inc, Biolase Inc, Bausch & Lomb Holdings, Cardiogenesis Corporation Inc, and Boston Scientific.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Powerful stocks to Increase Your Investments: Fiserv, Inc. (NASDAQ:FISV 0.54%), Boston Scientific Corporation (NYSE:BSX -1.04%) appeared first on Stocks Equity .

Major players in the interventional oncology devices market are Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Merit Medical Systems Inc, Philips Volcano, AngioDynamics Inc, GE Healthcare, Siemens Healthineers, Sirtex Medical, and Cook Medical Incorporated. Major players in the interventional oncology devices market are Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Merit Medical Systems Inc, Philips Volcano, AngioDynamics Inc, GE Healthcare, Siemens Healthineers, Sirtex Medical, and Cook Medical Incorporated.

Major players in the coronary atherectomy devices market are Boston Scientific, Philips, Cardiovascular Systems, Spectranetics, Medtronic, Avinger, BIOTRONIK, Arterial Remodeling Technologies, Atrium Medical, and B. Major players in the coronary atherectomy devices market are Boston Scientific, Philips, Cardiovascular Systems, Spectranetics, Medtronic, Avinger, BIOTRONIK, Arterial Remodeling Technologies, Atrium Medical, and B.

NEW YORK, Feb. 8, 2023 /PRNewswire/ -- Major players in the minimally invasive surgery devices market are Abbott Laboratories, GE Healthcare, Medtronic PLC, Siemens Healthineers, Smith & Nephew Plc., Medtronic Plc., Stryker Corporation, Boston Scientific Corporation, Ethicon Inc, and B….

Major players in the biopsy devices market are Becton Dickinson and Company (BD), Cook Medical, Argon Medical Devices, Hologic, Boston Scientific Corporation, Cardinal Health, B. Braun Melsungen AG, Medtronic, Devicor Medical Products, and Danaher Corporation (Leica Microsystem). Major players in the biopsy devices market are Becton Dickinson and Company (BD), Cook Medical, Argon Medical Devices, Hologic, Boston Scientific Corporation, Cardinal Health, B. Braun Melsungen AG, Medtronic, Devicor Medical Products, and Danaher Corporation (Leica Microsystem).

Major players in the urology medical lasers market are Olympus Corporation, Ethicon Inc, Stryker Corporation, Boston Scientific Corporation, Richard Wolf GmbH, Cook Medical Incorporated, Karl Storz SE & Co. Major players in the urology medical lasers market are Olympus Corporation, Ethicon Inc, Stryker Corporation, Boston Scientific Corporation, Richard Wolf GmbH, Cook Medical Incorporated, Karl Storz SE & Co.

DHC has seen its SMA50 which is now -7.99%. In looking the SMA 200 we see that the stock has seen a -50.38%. BSX has seen its SMA50 which is … The post Tiling stocks: Diversified Healthcare Trust (NASDAQ:DHC -3.70%), Boston Scientific Corporation (NYSE:BSX -1.73%) appeared first on Stocks Equity .

HBAN has seen its SMA50 which is now 6.09%. In looking the SMA 200 we see that the stock has seen a 12.00%. BSX has seen its SMA50 which is … The post Reasons To Keep this: Huntington Bancshares Incorporated (NASDAQ:HBAN -0.32%), Boston Scientific Corporation (NYSE:BSX 0.89%) appeared first on Stocks Equity .

The verdict was for patent infringement claims relating to Boston Scientific’s SYNERGY™ coronary stents sold by Boston Scientific Corporation.

AFRM has seen its SMA50 which is now 67.42%. In looking the SMA 200 we see that the stock has seen a -1.79%. BSX has seen its SMA50 which is … The post Morning Stock’s Buzzers: Affirm Holdings, Inc. (NASDAQ:AFRM -3.34%), Boston Scientific Corporation (NYSE:BSX 0.27%) appeared first on Stocks Equity .

The U.S. Food and Drug Administration ((FDA)) granted 510(k) clearance to Boston Scientific (BSX) LithoVue Elite Single-Use Digital Flexible Ureteroscope System.The company said the…

WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX) said Friday that it has received a 510(k) clearance from the U.S. Food and Drug Administration for the LithoVue Elite Single-Use Digital Flexib…

https://www.investing.com/news/pro/boston-scientific-pt-raised-to-55-at-jefferies-432SI-2994212

https://www.investing.com/news/pro/boston-scientific-pt-raised-to-56-at-raymond-james-432SI-2994000

https://www.investing.com/news/pro/boston-scientific-pt-raised-to-55-at-bofa-securities-432SI-2993995

https://www.investing.com/news/pro/boston-scientific-pt-raised-to-52-at-stifel-432SI-2993514

A jury in a federal court in Delaware has found that Boston Scientific''s Synergy coronary stents infringe a patent held by the University of Texas and licensed to TissueGen.

Boston Scientific Corporation (NYSE:NYSE:BSX) Q4 2022 Results Conference Call February 1, 2023 8:00 AM ETCompany ParticipantsLauren Tengler - Vice President, Investor RelationsMike Mahoney…

Boston Scientific Corp (NYSE: BSX ) generated Q4 revenues of $3.24 billion , in line with the Wall Street estimate. Sales increased 3.7% Y/Y on a reported basis, 8.7% on an operational basis, and 7.1% on an organic basis. The company achieved an adjusted EPS of $0.45, missing the consensus of $0.47. Revenues from … Full story available on Benzinga.com

Boston Scientific (NYSE: BSX ) has outperformed the market over the past 10 years by 9.38% on an annualized basis producing an average annual return of 19.75%. Currently, Boston Scientific has a market capitalization of $66.25 billion. Buying $1000 In BSX: If … Full story available on Benzinga.com

Thermo Fisher easily beat quarterly projections, while Boston Scientific was in line. TMO stock popped Wednesday while BSX stock also rose.

WASHINGTON (dpa-AFX) - Boston Scientific Corp (BSX) reported a profit for its fourth quarter that increased from the same period last year but missed the Street estimates.The company''s bottom line…

Boston Scientific Corp. stock slid 5% in premarket trade Wednesday, after the medical device maker missed profit estimates for the fourth quarter. The…

Boston Scientific earnings missed by $0.02, revenue was in line with estimates

Boston Scientific press release (BSX): Q4 Non-GAAP EPS of $0.45 misses by $0.02.Revenue of $3.24B (+3.5% Y/Y) in-line.Reported net sales of $3.242 billion, representing an increase…

MARLBOROUGH, Mass. , Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational 1 basis and 7.1 percent on an organic 2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions 3 . The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted 4 EPS of $0.45 for the period, which includes an approximate $0.04 negative impact of the Italian payback, compared to $0.45 a year ago. For the full year 2022, the company generated net sales of $12.682 billion , growing 6.7 percent on a reported basis, 11.1 percent on an operational 1 basis and 8.7 percent on an organic 2 basis, including a negative 50 basis point impact associated with the Italian government payback provisions, all compared to the prior year period.

Boston Scientific (BSX) is scheduled to announce Q4 earnings results on Wednesday, February 1st, before market open.The consensus EPS Estimate is $0.47 (+4.4% Y/Y) and the consensus Revenue…

Boston Scientific (NYSE: BSX ) is set to give its latest quarterly earnings report on Wednesday, 2023-02-01. Here''s what investors need to know before the announcement. Analysts estimate that Boston Scientific will report an earnings per share (EPS) of $0.47. Boston Scientific bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Morning Movers to Watch: Rivian Automotive, Inc. (NASDAQ:RIVN 1.83%), Boston Scientific Corporation (NYSE:BSX -0.51%) appeared first on Stocks Equity .